313 related articles for article (PubMed ID: 19807696)
1. Complement activation and disease: protective effects of hyperbilirubinaemia.
Basiglio CL; Arriaga SM; Pelusa F; Almará AM; Kapitulnik J; Mottino AD
Clin Sci (Lond); 2009 Oct; 118(2):99-113. PubMed ID: 19807696
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells.
Duvall MR; Hwang HY; Boackle RJ
Immunobiology; 2010 May; 215(5):395-405. PubMed ID: 19586684
[TBL] [Abstract][Full Text] [Related]
3. Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement activation.
Hair PS; Gronemus JQ; Crawford KB; Salvi VP; Cunnion KM; Thielens NM; Arlaud GJ; Rawal N; Krishna NK
Mol Immunol; 2010 Jan; 47(4):792-8. PubMed ID: 19896716
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of the classical pathway of complement by a novel C1q-binding peptide derived from the human astrovirus coat protein.
Gronemus JQ; Hair PS; Crawford KB; Nyalwidhe JO; Cunnion KM; Krishna NK
Mol Immunol; 2010; 48(1-3):305-13. PubMed ID: 20728940
[TBL] [Abstract][Full Text] [Related]
5. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation.
Groeneveld TW; Ramwadhdoebé TH; Trouw LA; van den Ham DL; van der Borden V; Drijfhout JW; Hiemstra PS; Daha MR; Roos A
Mol Immunol; 2007 Jul; 44(14):3608-14. PubMed ID: 17448537
[TBL] [Abstract][Full Text] [Related]
6. New insights into the molecular mechanisms of classical complement activation.
Kojouharova M; Reid K; Gadjeva M
Mol Immunol; 2010 Aug; 47(13):2154-60. PubMed ID: 20542571
[TBL] [Abstract][Full Text] [Related]
7. C1q interactions with cell surface receptors.
Tenner AJ
Behring Inst Mitt; 1989 Jul; (84):220-9. PubMed ID: 2679535
[TBL] [Abstract][Full Text] [Related]
8. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
9. [Effect of medicinal preparations on the complement: inhibition of subcomponent C1q binding to a target].
Bichucher AM; Kozlov LV
Eksp Klin Farmakol; 2007; 70(6):25-8. PubMed ID: 18318191
[TBL] [Abstract][Full Text] [Related]
10. Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin.
Matsushita M; Matsushita A; Endo Y; Nakata M; Kojima N; Mizuochi T; Fujita T
Proc Natl Acad Sci U S A; 2004 Jul; 101(27):10127-31. PubMed ID: 15218103
[TBL] [Abstract][Full Text] [Related]
11. C1 subcomponent complexes: basic and clinical aspects.
Laurell AB; Sjöholm AG
Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.
Nauta AJ; Bottazzi B; Mantovani A; Salvatori G; Kishore U; Schwaeble WJ; Gingras AR; Tzima S; Vivanco F; Egido J; Tijsma O; Hack EC; Daha MR; Roos A
Eur J Immunol; 2003 Feb; 33(2):465-73. PubMed ID: 12645945
[TBL] [Abstract][Full Text] [Related]
13. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
[TBL] [Abstract][Full Text] [Related]
14. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
Skliris A; Happonen KE; Terpos E; Labropoulou V; Børset M; Heinegård D; Blom AM; Theocharis AD
Eur J Immunol; 2011 Feb; 41(2):437-49. PubMed ID: 21268013
[TBL] [Abstract][Full Text] [Related]
15. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.
Butko P; Nicholson-Weller A; Wessels MR
J Immunol; 1999 Sep; 163(5):2761-8. PubMed ID: 10453019
[TBL] [Abstract][Full Text] [Related]
16. Activation of classical pathway of complement cascade by soluble oligomers of prion.
Dumestre-Pérard C; Osmundson J; Lemaire-Vieille C; Thielens N; Grives A; Favier B; Csopaki F; Jamin M; Gagnon J; Cesbron JY
Cell Microbiol; 2007 Dec; 9(12):2870-9. PubMed ID: 17991046
[TBL] [Abstract][Full Text] [Related]
17. Possible mechanisms of degradation of C1q in vivo and in vitro: role of macrophages.
Daha MR
Behring Inst Mitt; 1989 Jul; (84):42-6. PubMed ID: 2529843
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of the interaction of C1q with immunoglobulins and the classical pathway of complement activation by steroids and triterpenoids sulfates.
Bureeva S; Andia-Pravdivy J; Symon A; Bichucher A; Moskaleva V; Popenko V; Shpak A; Shvets V; Kozlov L; Kaplun A
Bioorg Med Chem; 2007 May; 15(10):3489-98. PubMed ID: 17383882
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
[TBL] [Abstract][Full Text] [Related]
20. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
Pearlstein E; Sorvillo J; Gigli I
J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
